RIOT vs. VIVO, OSTK, OXFD, AWH, SOFI, COOP, CLSK, WD, QFIN, and UPST
Should you be buying Riot Platforms stock or one of its competitors? The main competitors of Riot Platforms include Meridian Bioscience (VIVO), Overstock.com (OSTK), Oxford Immunotec Global (OXFD), Aspira Women's Health (AWH), SoFi Technologies (SOFI), Mr. Cooper Group (COOP), CleanSpark (CLSK), Walker & Dunlop (WD), Qifu Technology (QFIN), and Upstart (UPST).
Riot Platforms (NASDAQ:RIOT) and Meridian Bioscience (NASDAQ:VIVO) are both business services companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, community ranking, dividends, earnings, profitability, valuation and institutional ownership.
Riot Platforms has a net margin of 76.02% compared to Meridian Bioscience's net margin of 12.70%. Meridian Bioscience's return on equity of 16.74% beat Riot Platforms' return on equity.
Riot Platforms has a beta of 4.06, suggesting that its share price is 306% more volatile than the S&P 500. Comparatively, Meridian Bioscience has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
In the previous week, Riot Platforms had 6 more articles in the media than Meridian Bioscience. MarketBeat recorded 6 mentions for Riot Platforms and 0 mentions for Meridian Bioscience. Riot Platforms' average media sentiment score of 0.06 beat Meridian Bioscience's score of 0.00 indicating that Riot Platforms is being referred to more favorably in the media.
Meridian Bioscience has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.
Riot Platforms received 184 more outperform votes than Meridian Bioscience when rated by MarketBeat users. Likewise, 67.48% of users gave Riot Platforms an outperform vote while only 50.32% of users gave Meridian Bioscience an outperform vote.
40.3% of Riot Platforms shares are held by institutional investors. Comparatively, 89.7% of Meridian Bioscience shares are held by institutional investors. 4.4% of Riot Platforms shares are held by company insiders. Comparatively, 2.3% of Meridian Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Riot Platforms presently has a consensus price target of $17.83, indicating a potential upside of 83.41%. Given Riot Platforms' higher possible upside, equities research analysts plainly believe Riot Platforms is more favorable than Meridian Bioscience.
Summary
Riot Platforms beats Meridian Bioscience on 10 of the 17 factors compared between the two stocks.
Get Riot Platforms News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Riot Platforms Competitors List
Related Companies and Tools
